Whalesbook
India's pharmaceutical outsourcing sector is growing rapidly, leading to varied investment stories. While some Contract Development and Manufacturing Organization (CDMO) players are attracting significant attention, others are facing operational difficulties. Global drug companies are increasingly turning to Indian partners for complex development and manufacturing. The market is adjusting how it values these companies based on their execution, profitability, and strategic position.
The Indian CDMO industry is seeing strong global demand. Companies benefit from India's chemistry skills, large workforce, and cost advantages for outsourced drug development and manufacturing. The worldwide CDMO market is expected to hit roughly $268 billion by 2031. India's own drug discovery outsourcing market is projected to grow at a 10.8% annual rate from 2026 to 2033. Despite this strong industry trend, stock market performance is not uniform.
Stock Performance and Valuations Split
Recent data highlights a clear split in performance and valuation among top Indian CDMOs. Laurus Labs and Divis Laboratories are reporting strong revenue growth. However, their P/E ratios suggest much of this growth is already factored into their stock prices. Laurus Labs has P/E multiples between 62x and 99x, and its stock is up 79% year-over-year, trading well above its April 2025 low. Divis Laboratories is also trading above its April 2025 52-week low, with a 14% year-over-year gain.
In contrast, Syngene International's stock has fallen over 41% in the past year, nearing its March 2026 low, even after extending a key partnership with Bristol Myers Squibb. Adding to its struggles, it has a 'Strong Sell' rating from MarketsMOJO. Its P/E ratio of around 40x-50x seems high given its falling revenue and operational challenges. Gland Pharma, which focuses on injectables, shows more stable performance, with its stock mostly flat year-over-year and trading at a P/E of 32x-35x. Akums Drugs and Pharmaceuticals, a CDMO focused on formulations, has the lowest valuation at a P/E of about 23x, though its stock is down 7% over the past year and it typically operates with lower margins.
Key Strengths and Strategic Investments
Global pharmaceutical companies are outsourcing R&D and manufacturing to lower costs and speed up product launches. This trend benefits Indian CDMOs. Laurus Labs is investing in specialized areas like peptide development and antibody-drug conjugates. Divis Laboratories stands out with its API and custom synthesis strengths, supported by successful US FDA inspections. Syngene International's "science as a service" model, including its significant collaboration with Bristol Myers Squibb, is currently facing pressure from a customer-specific event that impacted its Q3 FY26 earnings. Gland Pharma is planning approximately ₹20 billion in capital expenditure to expand its capabilities in complex injectables and innovation-driven CDMO services.
Despite these strengths, market sentiment is becoming more selective. Syngene International’s revenue decline and negative analyst ratings stand in contrast to the growth shown by peers. Laurus Labs's strong CDMO segment growth and new modality investments come with a P/E ratio nearing 99x. This valuation relies heavily on sustained, high growth, making it vulnerable to any slowdown. Divis Laboratories, while stable, faces competition in generics, and its P/E over 68x leaves little room for error. Gland Pharma must manage its large capex plan amid fierce competition in sterile injectables. Akums Drugs, while cost-competitive, typically earns lower margins as a contract manufacturer. The sector also faces broader issues like shortages in fill-finish capacity and the continuous need to invest in advanced technologies, such as cell and gene therapies.
Key Risks for Investors
Despite the industry's growth, several risks are present for these CDMO companies. Syngene International's 'Strong Sell' rating highlights concerns over its recent revenue decline and a valuation that seems out of sync with its performance, especially considering its reliance on a single large customer, which creates concentration risk.
Laurus Labs's very high P/E ratios, some above 99x, indicate that investors expect extremely high, sustained growth. This valuation is precarious; any slowdown could lead to a sharp drop in stock price. Divis Laboratories, while stable, operates in competitive generic markets, and its high P/E ratio of over 68x leaves little room for mistakes.
Gland Pharma faces challenges in executing its significant capital expenditure plans amid fierce competition in sterile injectables. Akums Drugs, though cost-competitive, typically earns lower margins as a contract manufacturer. The entire sector also faces broader challenges, including shortages in fill-finish capacity and the continuous need to invest in advanced technologies like cell and gene therapies.
Outlook for CDMO Companies
The future success of these CDMO companies will depend on how they manage high valuation expectations, carry out strategic expansions, and broaden their revenue sources. Laurus Labs and Divis Laboratories must show ongoing profit growth to support their high stock valuations. Syngene International needs to show recovery from recent customer issues and find new clients to improve its performance. Gland Pharma and Akums Drugs plan to use their specialized skills and manufacturing capacity to gain more market share in outsourcing, focusing on cost efficiency to boost profits.